Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 3/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394588 | 0.97 | POLB (0.43) | POLBRAF1MAP2K1APPALDH1A1 | |
| SCHEMBL5406332 | 0.95 | RAF1 (0.46) | RAF1MAP2K1ALDH1A1KDM4EMAPT | |
| SCHEMBL4926471 | 0.86 | POLB (0.45) | POLBRAF1MAP2K1APPALDH1A1 | |
| SCHEMBL5401102 | 0.86 | FFAR1 (0.47) | POLBALDH1A1KDM4ELTB4RLTB4R2 | |
| SCHEMBL5401812 | 0.86 | LTB4R (0.43) | POLBALDH1A1KDM4ELTB4RLTB4R2 | |
| SCHEMBL5397151 | 0.85 | FFAR1 (0.46) | POLBALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL5398713 | 0.85 | KMT2A (0.50) | POLBRAF1MAP2K1APPALDH1A1 | |
| SCHEMBL5406787 | 0.85 | POLB (0.54) | POLBRAF1MAP2K1APPALDH1A1 | |
| SCHEMBL5407016 | 0.85 | RAB9A (0.43) | POLBALDH1A1MAPTTHRBMEN1 | |
| SCHEMBL5395656 | 0.85 | FFAR1 (0.39) | POLBRAF1MAP2K1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | POLB 527/4885RAF1 1038/4885MAP2K1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.